Stem cell secretome may outperform purified exosomes for neuroinflammation
Image generation failed.
For intranasal delivery, the therapeutically active unit of mesenchymal stromal cells may be the complete secretome - exosomes plus soluble factors - rather than purified exosomes alone.
The hypothesis is that MSC bioactivity is distributed across both vesicular cargo and soluble proteins. Purifying exosomes may therefore remove complementary signaling molecules and reduce overall potency.
Why this is plausible
MSC therapeutic effects are increasingly understood as predominantly paracrine. The secretome contains EVs alongside cytokines, chemokines, growth factors and other soluble bioactive molecules.
Intranasal MSC derived EVs have already shown activity in several preclinical CNS models, including hypoxic-ischemic brain injury, autoimmune neuroinflammation and stroke.
More interestingly, a 2026 study administered adipose stem cell concentrated conditioned medium intranasally after traumatic brain injury. Four doses improved learning and memory and reduced astrocyte activation and disease associated microglial signaling including TREM2, TYROBP, and APOE. PMID: 42342036
Outside the CNS, complete MSC conditioned medium has also been reported to produce greater anti-inflammatory activity than its isolated EV fraction. PMID: 37446034
Proposed experiment
Generate four products from the same MSC production batch:
- Whole concentrated secretome
- Purified EV fraction
- EV-depleted soluble fraction
- Recombined EV + soluble fraction
Normalize initially by producer cell equivalents, while independently reporting particle count, total protein and defined potency markers.
Compare intranasal dosing in a neuroinflammation model using microglial activation/inflammatory signaling as the primary endpoint, with BBB integrity and cognitive function as secondary endpoints.
Prediction: whole secretome and the recombined fraction will outperform either isolated fraction alone.
Falsification: if purified EVs match or exceed whole secretome at an appropriately normalized dose, the hypothesis is wrong.
The broader question: in trying to purify the active ingredient from the MSC secretome, are we actually removing part of the drug?
Supporting literature: PMID 42342036, 41192650, 38675108, 39700966, 39800240, 37446034